fcdabcaf

Seth Richards

Disclosure: I am in full compliance with all ethics and other policies for Market Realist research analysts. I am not invested in securities that I cover on Market Realist.

More From Seth Richards

  • uploads///Acq
    Company & Industry Overviews

    Mylan’s Recent Acquisitions Continue to Strengthen Its Position in International Markets

    Mylan takes an M&A strategy to save time related to compliance activities for obtaining regulatory approvals across various international markets.

    By Seth Richards
  • uploads///Risk
    Company & Industry Overviews

    Measuring Mylan’s Biggest Risks Moving Forward

    Aside from the risky generic pharmaceutical industry, Mylan faces company-specific business risks like country risk, foreign exchange risk, and M&A risk.

    By Seth Richards
  • uploads///acquisition
    Company & Industry Overviews

    Gauging Mylan’s Aggressive Acquisition Strategy

    By acquiring UDL Laboratories, Mylan entered the unit dose and the long-term care market. In 1998, Mylan added Penederm to its dermatological division.

    By Seth Richards
  • uploads///API
    Company & Industry Overviews

    How Has Manufacturing Its Own Active Pharmaceutical Ingredients Helped Mylan?

    Mylan is one of largest API (active pharmaceutical ingredient) manufacturers in the world, with nine API and intermediate manufacturing facilities.

    By Seth Richards
  • uploads///Therapeutic Area
    Company & Industry Overviews

    Mylan Product Portfolio across Key Therapeutic Areas

    Mylan is a leading pharmaceutical company that operates in more than 140 countries and operates across five different therapeutic areas.

    By Seth Richards
  • uploads///Prescription Drug
    Company & Industry Overviews

    Sizing up Mylan’s Blockbuster Drugs: Perforomist, Ultiva, and Emsam

    Mylan NV is the generic drug leader in the US prescription drug market with blockbuster drugs such as Perforomist, Ultiva, and Emsam.

    By Seth Richards
  • uploads///EpiPen Auto Injector
    Company & Industry Overviews

    Assessing the Role of the EpiPen Auto-Injector in Mylan’s Revenues

    Used to deliver Epinephrine in the treatment of severe allergic reactions, Mylan’s EpiPen auto-injectors hold the number one rank in the epinephrine market.

    By Seth Richards
  • uploads///Business Model
    Company & Industry Overviews

    Mylan’s Business Model: A Key Investor Rundown

    In 2014, Mylan earned about 85% of its total revenues from the US generic market, which is the largest generic market in the world.

    By Seth Richards
  • uploads///Geographic Segment
    Company & Industry Overviews

    Locating Mylan’s Geographic Market Strategy

    Compared to peers Teva Pharmaceuticals, Valeant Pharmaceuticals, and Zoetis, Mylan earns substantially higher revenues from the US generic market.

    By Seth Richards
  • Introducing Mylan, a Big International Gun in Generic Pharmaceuticals
    Company & Industry Overviews

    Introducing Mylan, a Big International Gun in Generic Pharmaceuticals

    Headquartered in the UK, Mylan is one of the biggest players in the generic pharmaceutical industry. It was founded by Milan Puskar and Don Panoj in 1961.

    By Seth Richards
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.